4,082 reports of this reaction
1.4% of all CYCLOPHOSPHAMIDE reports
#19 most reported adverse reaction
WHITE BLOOD CELL COUNT DECREASED is the #19 most commonly reported adverse reaction for CYCLOPHOSPHAMIDE, manufactured by Avyxa Pharma, LLC. There are 4,082 FDA adverse event reports linking CYCLOPHOSPHAMIDE to WHITE BLOOD CELL COUNT DECREASED. This represents approximately 1.4% of all 284,202 adverse event reports for this drug.
Patients taking CYCLOPHOSPHAMIDE who experience white blood cell count decreased should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
WHITE BLOOD CELL COUNT DECREASED is a less commonly reported adverse event for CYCLOPHOSPHAMIDE, but still significant enough to appear in the safety profile.
In addition to white blood cell count decreased, the following adverse reactions have been reported for CYCLOPHOSPHAMIDE:
The following drugs have also been linked to white blood cell count decreased in FDA adverse event reports:
WHITE BLOOD CELL COUNT DECREASED has been reported as an adverse event in 4,082 FDA reports for CYCLOPHOSPHAMIDE. This does not prove causation, but indicates an association observed in post-market surveillance data.
WHITE BLOOD CELL COUNT DECREASED accounts for approximately 1.4% of all adverse event reports for CYCLOPHOSPHAMIDE, making it a notable side effect.
If you experience white blood cell count decreased while taking CYCLOPHOSPHAMIDE, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.